ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Factor VIII Mimetics"
Episode Synopsis
Abstract 4: Effectiveness of emicizumab in hemophilia A: A 4th interim analysis of the real-world study EMIIL Abstract 5: Prospective evaluation of a defined replacement protocol for peri-operative hemostasis in patients with severe hemophilia A with and without inhibitors on emicizumab prophylaxis undergoing elective major surgeries-final results. (EmiSurg Study)Abstract 6: FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab
More episodes of the podcast Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies
Conclusions
08/08/2025
A Focus on Rebalancing Agents
01/08/2025
In God we trust